Oricell Therapeutics said its GPC3-targeted autologous CAR T, Ori-C101, is entering a confirmatory registration Phase 2 trial for patients with GPC3-positive advanced hepatocellular carcinoma. The program targets an unmet need in liver cancer, where prior cell therapies have faced challenges around target selection and consistent clinical activity. Oricell is positioning Ori-C101 as the first GPC3-directed immune cell therapy—and the first CAR T therapy for liver cancer—to reach that confirmatory stage of development. If successful, the trial outcome could shape future CAR T targeting strategies for solid tumors. For the field, the move underscores a continuing shift from early proof-of-concept toward registration-ready designs in next-generation CAR T programs with differentiated tumor targets.